Filed pursuant to Rule No. 424(b)(3)
                                          File Number 333-72626


PROSPECTUS SUPPLEMENT NO. 6
(To Prospectus dated December 3, 2001)

                                 $1,483,179,000
                               [GRAPHIC OMITTED]
      Contingent Zero-Coupon Accreting Redeemable SecuritiesSM (CZARSSM)
                      (Convertible Senior Notes) Due 2021
                                      and
                          Common Stock Issuable upon
                            Conversion of the CZARS


         This prospectus supplement supplements the prospectus dated December
3, 2001, as supplemented, of U.S. Bancorp relating to the sale by certain of
our securityholders (including their pledgees, donees, assignees, transferees,
successors and others who later hold any of the selling securityholders'
interests) of up to $1,483,179,000 aggregate principal amount at maturity of
CZARS and the shares of common stock issuable upon conversion of the CZARS.
You should read this prospectus supplement in conjunction with the prospectus,
and this prospectus supplement is qualified by reference to the prospectus,
except to the extent that the information in this prospectus supplement
supersedes the information contained in the prospectus.

         Investing in the CZARS or shares of common stock involves risks that
are described in the "Risk Factors" section beginning on page 8 of the
prospectus.

         Neither the Securities and Exchange Commission, any state securities
commission nor any other regulatory body has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.

            The date of this prospectus supplement is August 23, 2002.





         On August 6, 2002, we repurchased $1,407,284,000 aggregate principal
amount at maturity of CZARS, submitted to us by holders in accordance with the
terms of the indenture governing the CZARS. $75,895,000 aggregate principal
amount at maturity of CZARS remain outstanding.

         The table of selling securityholders contained in the prospectus is
hereby amended to add the entity named below as a selling securityholder:




                                                               Number of
                                                               Shares of
                        Aggregate Principal      Percentage   Common Stock    Percentage of
                       Amount at Maturity of      of CZARS     That May be    Common Stock

Name(1)                CZARS That May be Sold    Outstanding    Sold(2)       Outstanding(3)
-------------------    ----------------------   ------------- ------------   ---------------
UBS AG LON F/B/O PB         $15,000,000             19.8%       362,145            *

                                                                 





*   Less than one percent (1%).
(1) Information about other selling securityholders will be set forth in
    prospectus supplements, if required.
(2) Assumes conversion of all of the holder's CZARS at a conversion rate of
    24.1430 shares of common stock per $1,000 principal amount at maturity of
    the CZARS. This conversion rate is subject to adjustment, however, as
    described under "Description of the CZARS--Conversion rights" in the
    attached prospectus. As a result, the number of shares of common stock
    issuable upon conversion of the CZARS may increase or decrease in the
    future.
(3) Calculated based on Rule 13d-3(d)(1)(i) of the Exchange Act, using
    1,969,001,279 shares of common stock outstanding as of September 30, 2001.
    In calculating this amount for each holder, we treated as outstanding the
    number of shares of common stock issuable upon conversion of all of that
    holder's CZARS, but we did not assume conversion of any other holder's
    CZARS.